Compounds > yttrium radioisotopes
Page last updated: 2024-08-26

yttrium radioisotopes and Bone Marrow Diseases

yttrium radioisotopes has been researched along with Bone Marrow Diseases in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bander, NH; Goldsmith, SJ; Hamacher, KA; Konishi, S; Kostakoglu, L; Milowski, MI; Nanus, DM; Vallabhajosula, S1
Bartolomei, M; Bodei, L; Boiardi, A; Botturi, A; Broggi, G; Eoli, M; Lamperti, E; Milanesi, I; Paganelli, G; Rocca, P; Salmaggi, A; Silvani, A1
Eckersberg-Rhodes, TE; Erwin, WD; Groch, MW; Kelly, ME; Nannapaneni, M; Rao, P; Spies, SM1

Trials

3 trial(s) available for yttrium radioisotopes and Bone Marrow Diseases

ArticleYear
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Body Burden; Bone Marrow; Bone Marrow Diseases; Dose-Response Relationship, Radiation; Humans; Lutetium; Male; Maximum Tolerated Dose; Middle Aged; Organ Specificity; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Injuries; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Relative Biological Effectiveness; Yttrium Radioisotopes

2005
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
    Journal of neuro-oncology, 2005, Volume: 72, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Delivery Systems; Glioblastoma; Humans; Infusions, Intralesional; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Radioimmunotherapy; Yttrium Radioisotopes

2005
Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
    Nuclear medicine communications, 2001, Volume: 22, Issue:2

    Topics: Algorithms; Antibodies, Monoclonal; Antigens, CD20; Blood Cell Count; Bone Marrow; Bone Marrow Diseases; Humans; Lymphoma, Non-Hodgkin; Predictive Value of Tests; Radioimmunotherapy; Radiometry; Spine; Yttrium Radioisotopes

2001